Cancer proteomics: developments in technology, clinical use and commercialization

Reference

• Diamandis EP. Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol. Metab 1998;9(8):310-16
   Google Scholar
• Ghazalpour A, Bennett B, Petyuk VA, et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 2011;7(6):e1001393
   PubMed Web of Science ®Google Scholar
• Rogers S, Girolami M, Kolch W, et al. Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics 2008;24(24):2894-900
   PubMed Web of Science ®Google Scholar
• Paulo JA, Kadiyala V, Banks PA, et al. Mass spectrometry-based quantitative proteomic profiling of human pancreatic and hepatic stellate cell lines. Genomics Proteomics Bioinformatics 2013;11(2):105-13
   PubMedGoogle Scholar
• Toss A, De Matteis E, Rossi E, et al. Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci 2013;14(4):8271-90
   PubMedGoogle Scholar
• Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10(1):13
   PubMed Web of Science ®Google Scholar
• Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. biomark Insights 2007;1:1-48
   PubMedGoogle Scholar
• Gupta S, Venkatesh A, Ray S, Srivastava S. Challenges and prospects for biomarker research: A current perspective from the developing world. Biochim Biophys Acta 2014;1844(5):899-908
   PubMed Web of Science ®Google Scholar
• Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011;8(1):61-79
   PubMed Web of Science ®Google Scholar
• Rosenblatt KP, Huebschman ML, Garner HR. Construction and hyperspectral imaging of quantum dot lysate arrays [Internet]. In: Espina V, Liotta LA, editors. Molecular profiling. Humana Press; 2012. 311-24. Available from: http://link.springer.com/protocol/10.1007/978-1-60327-216-2_20 [Cited 14 July 2014]
   Google Scholar
• Järås K, Ressine A, Nilsson E, et al. Reverse-phase versus sandwich antibody microarray, technical comparison from a clinical perspective. Anal Chem 2007;79(15):5817-25
   PubMedGoogle Scholar
• Pla-Roca M, Leulmi RF, Tourekhanova S, et al. Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples. Mol Cell Proteomics 2012;11(4):M111.011460
   PubMedGoogle Scholar
• Gonzalez-Gonzalez M, Jara-Acevedo R, Matarraz S, et al. Nanotechniques in proteomics: Protein microarrays and novel detection platforms. Eur J Pharm Sci 2012;45(4):499-506
   PubMed Web of Science ®Google Scholar
• Cretich M, Damin F, Chiari M. Protein microarray technology: how far off is routine diagnostics? The Analyst 2014;139(3):528
   PubMedGoogle Scholar
• Pin E, Fredolini C, Petricoin EFIII. The role of proteomics in prostate cancer research: Biomarker discovery and validation. Clin Biochem 2013;46(6):524-38
   PubMedGoogle Scholar
• Radom F, Jurek PM, Mazurek MP, et al. Aptamers: Molecules of great potential. Biotechnol Adv 2013;31(8):1260-74
   PubMedGoogle Scholar
• Song Q, Josef Stadler LK, Peng J, Ko Ferrigno P. Peptide Aptamer Microarrays: Bridging the bio–detector interface. Faraday Discuss 2011;149:79
   PubMedGoogle Scholar
• Sokolowska I, Wetie AGN, Woods AG, Darie CC. Applications of mass spectrometry in proteomics. Aust J Chem 2013;66(7):721-33
   Google Scholar
• Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014;3:7
   PubMedGoogle Scholar
• Bantscheff M, Lemeer S, Savitski MM, Kuster B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal Bioanal Chem 2012;404(4):939-65
   PubMed Web of Science ®Google Scholar
• DeSouza LV, Siu KWM. Mass spectrometry-based quantification. Clin Biochem 2013;46(6):421-31
   PubMed Web of Science ®Google Scholar
• Bensimon A, Heck AJR, Aebersold R. Mass spectrometry–based proteomics and network biology. Annu Rev Biochem 2012;81(1):379-405
   PubMedGoogle Scholar
• Domon B, Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol 2010;28(7):710-21
   PubMed Web of Science ®Google Scholar
• Zhang H, Ge Y. Comprehensive analysis of protein modifications by top-down mass spectrometry. Circ Cardiovasc Genet 2011;4(6):711
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fonslow BR, Shan B, et al. Protein Analysis by Shotgun/Bottom-up Proteomics. Chem Rev 2013;113(4):2343-94
   PubMed Web of Science ®Google Scholar
• Wu C, Tran JC, Zamdborg L, et al. A protease for “middle-down” proteomics. Nat Methods 2012;9(8):822-4
   PubMedGoogle Scholar
• Tsiatsiani L, Heck AJR. Proteomics beyond trypsin. FEBS J 2015;10.1111/febs.13287. [Epub ahead of print]
   PubMedGoogle Scholar
• Laskay ÜA, Srzentić K, Monod M, Tsybin YO. Extended bottom-up proteomics with secreted aspartic protease Sap9. J Proteomics 2014;110:20-31
   PubMedGoogle Scholar
• Chambers AG, Percy AJ, Simon R, Borchers CH. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics 2014;11(2):137-48
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Present and future of cancer biomarkers. Clin Chem Lab Med 2014;52(6):791-4
   PubMedGoogle Scholar
• Wegdam W, Moerland PD, Meijer D, et al. A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. Proteome Sci 2012;10(1):45
   PubMedGoogle Scholar
• Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010;56(2):327-9
   PubMed Web of Science ®Google Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation – Quality assurance and control of protein biomarker assays. Mol Oncol 2014;8(4):840-58
   PubMed Web of Science ®Google Scholar
• Razavi M, Frick LE, LaMarr WA, et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res 2012;11(12):5642-9
   PubMed Web of Science ®Google Scholar
• Mayo Medical Laboratories. Serum Thyroglobulin Testing Using SISCAPA Technology Now Available [Internet]. Mayo Med Lab. Available from: http://news.mayomedicallaboratories.com/2014/04/07/serum-thyroglobulin-testing-using-siscapa-technology-now-available/
   Google Scholar
• Kushnir MM, Rockwood AL, Roberts WL, et al. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 2013;59(6):982-90
   PubMed Web of Science ®Google Scholar
• Wilson R. Sensitivity and specificity: twin goals of proteomics assays. Can they be combined? Expert Rev Proteomics 2013;10(2):135-49
   PubMed Web of Science ®Google Scholar
• Hembrough T, Thyparambil S, Liao W-L, et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn 2013;15(4):454-65
   PubMed Web of Science ®Google Scholar
• Catenacci DVT, Liao W-L, Thyparambil S, et al. Absolute Quantitation of met using mass spectrometry for clinical application: assay precision, stability, and correlation with met gene amplification in FFPE tumor tissue. PLoS One 2014;9(7):e100586
   PubMed Web of Science ®Google Scholar
• Poste G. Bring on the biomarkers. Nature 2011;469(7329):156-7
   PubMed Web of Science ®Google Scholar
• Moore HM, Compton CC, Alper J, Vaught JB. International approaches to advancing biospecimen science. Cancer Epidemiol Biomarkers Prev 2011;20(5):729-32
   PubMed Web of Science ®Google Scholar
• Chaurand P. Imaging mass spectrometry of thin tissue sections: A decade of collective efforts. J Proteomics 2012;75(16):4883-92
   PubMed Web of Science ®Google Scholar
• Oezdemir RF, Gaisa NT, Lindemann-Docter K, et al. Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasia. Clin Biochem 2012;45(1-2):7-11
   PubMedGoogle Scholar
• Gustafsson JOR, Oehler MK, Ruszkiewicz A, et al. MALDI imaging mass spectrometry (MALDI-IMS)–application of spatial proteomics for ovarian cancer classification and diagnosis. Int J Mol Sci 2011;12(1):773-94
   PubMed Web of Science ®Google Scholar
• Tan HT, Lee YH, Chung MCM. Cancer proteomics. Mass Spectrom Rev 2012;31(5):583-605
   PubMed Web of Science ®Google Scholar
• Rusling JF, Kumar CV, Gutkind JS, Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. The Analyst 2010;135(10):2496
   PubMed Web of Science ®Google Scholar
• Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012;118(1):91-100
   PubMed Web of Science ®Google Scholar
• Pavlou MP, Diamandis EP, Blasutig IM. The Long Journey of Cancer Biomarkers from the Bench to the Clinic. Clin Chem 2013;59(1):147-57
   PubMed Web of Science ®Google Scholar
• Sauter ER. The quest for reliable biomarkers to identify new and recurrent cancer. Biomark Med 2012;6(5):561-2
   PubMedGoogle Scholar
• Kaur S, Baine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 2012;6(5):597-612
   PubMed Web of Science ®Google Scholar
• Prieto PA, Cha CH. DKK1 as a serum biomarker for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013;2(3):127-8
   PubMedGoogle Scholar
• Ladabaum U, Allen J, Wandell M, Ramsey S. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev 2013;22(9):1567-76
   PubMed Web of Science ®Google Scholar
• Xiang D, Zhang B, Doll D, et al. Lung cancer screening: from imaging to biomarker. Biomark Res 2013;1(1):1-10
   PubMedGoogle Scholar
• Moyer VA. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012;157(2):120-34
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102(19):1462-7
   PubMedGoogle Scholar
• Hori SS, Gambhir SS. Mathematical model identifies blood biomarker–based early cancer detection strategies and limitations. Sci Transl Med 2011;3(109):109ra116-16
   PubMedGoogle Scholar
• Kwong GA, von Maltzahn G, Murugappan G, et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 2013;31(1):63-70
   PubMed Web of Science ®Google Scholar
• Luna Coronell JA, Syed P, Sergelen K, et al. The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics. J Proteomics 2012;76:102-15
   PubMed Web of Science ®Google Scholar
• Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer 2015;136(10):2243-52
   PubMed Web of Science ®Google Scholar
• Zayakin P, Ancāns G, Siliņa K, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer 2013;132(1):137-47
   PubMedGoogle Scholar
• Leung F, Diamandis EP, Kulasingam V. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 2012;6(5):613-25
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10(4):327-40
   PubMed Web of Science ®Google Scholar
• Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008;59(3):377-84
   PubMedGoogle Scholar
• Yamashita F, Azuma K, Yoshida T, et al. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS ONE 2013;8(8):e71356
   PubMed Web of Science ®Google Scholar
• Bepler G, Olaussen KA, Vataire A-L, et al. ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. Am J Pathol 2011;178(1):69-78
   PubMedGoogle Scholar
• Friboulet L, Olaussen KA, Pignon J-P, et al. ERCC1 isoform expression and DNA repair in non–small-cell lung cancer. N Engl J Med 2013;368(12):1101-10
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8(4):307-25
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 2008;102(2):128-31
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25(5):637-50
   PubMed Web of Science ®Google Scholar
• Liotta LA, Iii EFP. Regulatory approval pathways for molecular diagnostic technology [Internet]. In: Espina V, Liotta LA, editors. Molecular profiling. Humana Press, 2012.409-20. Available from: http://link.springer.com/protocol/10.1007/978-1-60327-216-2_27. [Cited 14 August 2014]
   Google Scholar
• Srinivas PR, Srivastava S, Hanash S, Wright GL. Proteomics in Early Detection of Cancer. Clin Chem 2001;47(10):1901-11
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3(4):267-75
   PubMed Web of Science ®Google Scholar
• Sokoll LJ, Sanda MG, Feng Z, et al. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19(5):1193-200
   PubMedGoogle Scholar
• Loeb S, Sokoll LJ, Broyles DL, et al. Prospective Multicenter evaluation of the beckman coulter prostate health index using who calibration. J Urol 2013;189(5):1702-6
   PubMedGoogle Scholar
• Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104(5):863-70
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Agarwal N, Beard C, et al. Testicular cancer. J Natl Compr Canc Netw 2012;10(4):502-35
   PubMedGoogle Scholar
• Hoff DDV, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28(33):4877-83
   PubMedGoogle Scholar
• Russell K, Shunyakov L, Dicke KA, et al. A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service. Front. Pharmacol. [Internet] 2014.5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997001/
   Google Scholar
• Hirales Casillas CE, Flores Fernández JM, Camberos EP, et al. Current status of circulating protein biomarkers to aid the early detection of lung cancer. Future Oncol 2014;10(8):1501-13
   PubMedGoogle Scholar
• Woodcock J, Repoli A, Michael S, Lebowitz The Development and Validation of Paula’s Test [Internet]. 2012. Available from: http://genesysbiolabs.com/wp-content/uploads/2013/11/Development-and-Validation-of-PAULA%C2%B9s-Test_white-paper.pdf
   Google Scholar
• Bateman NW, Sun M, Bhargava R, et al. Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. J Proteome Res 2011;10(3):1323-32
   PubMedGoogle Scholar
• DeSouza LV, Krakovska O, Darfler MM, et al. mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. Proteomics 2010;10(17):3108-16
   PubMed Web of Science ®Google Scholar
• Huang SK, Darfler MM, Nicholl MB, et al. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS ONE 2009;4(2):e4430
   Google Scholar
• Hembrough T, Thyparambil S, Liao W-L, et al. Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue. Clin Proteomics 2012;9(1):5
   PubMedGoogle Scholar
• McKinsey & company. personalized medicine the way forward [Internet]. Available from: http://www.mckinsey.com/∼/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/McKinsey%20on%20Personalized%20Medicine%20March%202013.ashx
   Google Scholar
• Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov 2009;8(4):279-86
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. In Vitro Diagnostics - List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) [Internet]. 2014. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
   Google Scholar
• Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012;18(3):619-24
   PubMed Web of Science ®Google Scholar
• Walter Koch. Companion Diagnostics: A Blossoming Field [Internet]. 2011. Available from: http://www.ivdtechnology.com/print/2626
   Google Scholar
• Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20(6):1453-7
   PubMed Web of Science ®Google Scholar
• Fridlyand J, Simon RM, Walrath JC, et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013;12(10):743-55
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. Companion diagnostics in oncology - current status and future aspects. Oncology 2013;85(1):59-68
   PubMedGoogle Scholar
• US Food and Drug Administration. Anticipated Details of the Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) [Internet]. 2014. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf
   Google Scholar
• US Food and Drug Administration. Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs) [Internet]. 2014. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm416684.pdf
   Google Scholar
• US Food and Drug Administration. Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories: Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) [Internet]. 2014. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.pdf
   Google Scholar
• Klein RD. Molecular diagnostics: molecular med Tri-Con 2013. Expert Rev Mol Diagn 2013;13(6):527-8
   PubMed Web of Science ®Google Scholar
• Malone B. Molecular diagnostics reimbursement in flux. Clin Lab News 2013;39:1
   Google Scholar
• Saad AJ. The Future of Pathology Is Now. Arch Pathol Lab Med 2013;138(1):9-11
   Google Scholar
• Cohen JP, Felix AE. Personalized medicine’s bottleneck: diagnostic test evidence and reimbursement. J Pers Med 2014;4(2):163-75
   PubMedGoogle Scholar
• Trusheim MR, Austin MF, Rausch C, Berndt ER. Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. Pharmacogenomics 2013;14(3):325-34
   PubMedGoogle Scholar
• Garau M, Towse A, Garrison L, et al. Can and should value-based pricing be applied to molecular diagnostics? Pers Med 2012;10(1):61-72
   Google Scholar
• Hood BL, Malehorn DE, Conrads TP, Bigbee WL. Serum Proteomics Using Mass Spectrometry [Internet]. In: Tainsky MA, editor. Tumor biomarker discovery. Humana Press; 2009. 107-28. Available from: http://link.springer.com/protocol/10.1007/978-1-60327-811-9_8 [Cited 14 July 2014]
   Google Scholar
• Wang Q, Chaerkady R, Wu J, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 2011;108(6):2444-9
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572-7
   PubMed Web of Science ®Google Scholar
• Check E. Proteomics and cancer: Running before we can walk? Nature 2004;429(6991):496-7
   PubMed Web of Science ®Google Scholar
• Wagner L. A test before its time? FDA stalls distribution process of proteomic test. J Natl Cancer Inst 2004;96(7):500-1
   PubMedGoogle Scholar
• Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 2006;66(11):5540-1
   PubMed Web of Science ®Google Scholar
• Maurer K, Eschrich K, Schellenberger W, et al. Oral brush biopsy analysis by MALDI-ToF Mass Spectrometry for early cancer diagnosis. Oral Oncol 2013;49(2):152-6
   PubMedGoogle Scholar
• Brégeon F, Brioude G, De Dominicis F, et al. MALDI-ToF mass spectrometry for the rapid diagnosis of cancerous lung nodules. PLoS One 2014;9(5):e97511
   Google Scholar
• Velstra B, Bonsing BA, Mertens BJ, et al. Detection of pancreatic cancer using serum protein profiling. HPB 2013;15(8):602-10
   PubMedGoogle Scholar
• Sawyers CL. The cancer biomarker problem. Nature 2008;452(7187):548-52
   PubMed Web of Science ®Google Scholar